Cited 15 times in
Combination of topotecan and etoposide as a salvage treatment for patients with recurrent small cell lung cancer following irinotecan and platinum first-line chemotherapy.
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 조병철 | - |
dc.contributor.author | 최혜진 | - |
dc.contributor.author | 김세규 | - |
dc.contributor.author | 김주항 | - |
dc.contributor.author | 손주혁 | - |
dc.contributor.author | 신상준 | - |
dc.contributor.author | 장준 | - |
dc.contributor.author | 전성하 | - |
dc.contributor.author | 정종열 | - |
dc.date.accessioned | 2015-05-19T16:38:10Z | - |
dc.date.available | 2015-05-19T16:38:10Z | - |
dc.date.issued | 2008 | - |
dc.identifier.issn | 0344-5704 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/106666 | - |
dc.description.abstract | PURPOSE: The efficacy and safety of a combined regimen of topotecan and etoposide was tested in patients with relapsed or refractory small-cell lung cancer. PATIENTS AND METHODS: From October 2003 to May 2005, 23 patients who have failed to the previous irinotecan and platinum chemotherapy received intravenous topotecan 1 mg/m2 (day 1-5) and etoposide 80 mg/m2 (day 1-3). Treatment was repeated every 21 days for a maximum of 6 cycles. RESULTS: Twelve patients were refractory to first-line chemotherapy. Seventeen patients (73.9%) were male and the median age was 63 years. ECOG performance status was 0-1 in 13 (56.5%) patients. The median cycles of chemotherapy was three. Twenty-one patients were assessable for response evaluation. The overall response rate was 17.4% (0 CR, 4 PR, 7 SD, 10 PD) under the intent-to-treat analysis. Two sensitive case patients and two refractory case patients achieved partial response. After a median follow-up of 20.8 months, median progression free survival was 4.7 months and median overall survival was 9.5 months. The estimated 1-year survival rate was 38.7%. All patients were assessable for toxicity and major toxicities were myelosuppression. Grade 3/4 neutropenia and thrombocytopenia occurred in 18 (78.3%) and 12 (52.2%) patients, respectively. Grade 3/4 febrile neutropenia occurred in two patients (8.7%) and infection in three patients (13.0%). There was one treatment-related death due to pneumonia. CONCLUSION: This salvage regimen showed modest efficacy and manageable toxicities. Further study will be required in recurrent SCLC patients pretreated irinotecan and platinum. | - |
dc.description.statementOfResponsibility | open | - |
dc.format.extent | 309~313 | - |
dc.relation.isPartOf | CANCER CHEMOTHERAPY AND PHARMACOLOGY | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Aged | - |
dc.subject.MESH | Antineoplastic Agents/administration & dosage | - |
dc.subject.MESH | Antineoplastic Agents, Phytogenic/administration & dosage | - |
dc.subject.MESH | Antineoplastic Combined Chemotherapy Protocols/adverse effects | - |
dc.subject.MESH | Antineoplastic Combined Chemotherapy Protocols/therapeutic use* | - |
dc.subject.MESH | Camptothecin/administration & dosage | - |
dc.subject.MESH | Camptothecin/analogs & derivatives | - |
dc.subject.MESH | Carcinoma, Small Cell/drug therapy* | - |
dc.subject.MESH | Carcinoma, Small Cell/pathology | - |
dc.subject.MESH | Combined Modality Therapy | - |
dc.subject.MESH | Endpoint Determination | - |
dc.subject.MESH | Etoposide/administration & dosage | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Hematologic Diseases/chemically induced | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Lung Neoplasms/drug therapy* | - |
dc.subject.MESH | Lung Neoplasms/pathology | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Organoplatinum Compounds/administration & dosage | - |
dc.subject.MESH | Patient Compliance | - |
dc.subject.MESH | Salvage Therapy* | - |
dc.subject.MESH | Topotecan/administration & dosage | - |
dc.title | Combination of topotecan and etoposide as a salvage treatment for patients with recurrent small cell lung cancer following irinotecan and platinum first-line chemotherapy. | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학) | - |
dc.contributor.googleauthor | Hye Jin Choi | - |
dc.contributor.googleauthor | Byoung Chul Cho | - |
dc.contributor.googleauthor | Sang Joon Shin | - |
dc.contributor.googleauthor | Seong Ha Cheon | - |
dc.contributor.googleauthor | Jong Yul Jung | - |
dc.contributor.googleauthor | Joon Chang | - |
dc.contributor.googleauthor | Se Kyu Kim | - |
dc.contributor.googleauthor | Joo Hyuk Sohn | - |
dc.contributor.googleauthor | Joo Hang Kim | - |
dc.identifier.doi | 10.1007/s00280-007-0505-9 | - |
dc.admin.author | false | - |
dc.admin.mapping | false | - |
dc.contributor.localId | A03822 | - |
dc.contributor.localId | A04219 | - |
dc.contributor.localId | A00602 | - |
dc.contributor.localId | A00945 | - |
dc.contributor.localId | A01995 | - |
dc.contributor.localId | A02105 | - |
dc.contributor.localId | A03472 | - |
dc.contributor.localId | A03520 | - |
dc.contributor.localId | A03721 | - |
dc.relation.journalcode | J00437 | - |
dc.identifier.eissn | 1432-0843 | - |
dc.identifier.pmid | 17576560 | - |
dc.identifier.url | http://link.springer.com/article/10.1007%2Fs00280-007-0505-9 | - |
dc.subject.keyword | Etoposide | - |
dc.subject.keyword | Irinotecan | - |
dc.subject.keyword | Small Cell Lung Cancer | - |
dc.subject.keyword | Topotecan | - |
dc.subject.keyword | Eastern Cooperative Oncology Group Performance Status | - |
dc.contributor.alternativeName | Cho, Byoung Chul | - |
dc.contributor.alternativeName | Choi, Hye Jin | - |
dc.contributor.alternativeName | Kim, Se Kyu | - |
dc.contributor.alternativeName | Kim, Joo Hang | - |
dc.contributor.alternativeName | Sohn, Joo Hyuk | - |
dc.contributor.alternativeName | Shin, Sang Joon | - |
dc.contributor.alternativeName | Chang, Joon | - |
dc.contributor.alternativeName | Cheon, Seong Ha | - |
dc.contributor.alternativeName | Jung, Jong Yul | - |
dc.contributor.affiliatedAuthor | Cho, Byoung Chul | - |
dc.contributor.affiliatedAuthor | Choi, Hye Jin | - |
dc.contributor.affiliatedAuthor | Kim, Se Kyu | - |
dc.contributor.affiliatedAuthor | Kim, Joo Hang | - |
dc.contributor.affiliatedAuthor | Sohn, Joo Hyuk | - |
dc.contributor.affiliatedAuthor | Shin, Sang Joon | - |
dc.contributor.affiliatedAuthor | Chang, Joon | - |
dc.contributor.affiliatedAuthor | Cheon, Seong Ha | - |
dc.contributor.affiliatedAuthor | Jung, Jong Yul | - |
dc.rights.accessRights | not free | - |
dc.citation.volume | 61 | - |
dc.citation.number | 2 | - |
dc.citation.startPage | 309 | - |
dc.citation.endPage | 313 | - |
dc.identifier.bibliographicCitation | CANCER CHEMOTHERAPY AND PHARMACOLOGY, Vol.61(2) : 309-313, 2008 | - |
dc.identifier.rimsid | 46645 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.